Literature DB >> 9415899

Opposing roles of the amygdala and dorsolateral periaqueductal gray in fear-potentiated startle.

D L Walker1, J V Cassella, Y Lee, T C De Lima, M Davis.   

Abstract

The whole-body acoustic startle response is a short-latency reflex mediated by a relatively simple neural circuit in the lower brainstem and spinal cord. The amplitude of this reflex is markedly enhanced by moderate fear levels, and less effectively increased by higher fear levels. Extensive evidence indicates that the amygdala plays a key role in the potentiation of startle by moderate fear. More recent evidence suggests that the periaqueductal gray is involved in the loss of potentiated startle at higher levels of fear. The influence of both structures may be mediated by anatomical connections with the acoustic startle circuit, perhaps at the level of the nucleus reticularis pontis caudalis. The present chapter reviews these data.

Entities:  

Mesh:

Year:  1997        PMID: 9415899     DOI: 10.1016/s0149-7634(96)00061-9

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  25 in total

1.  Effects of acute ethanol or amphetamine administration on the acoustic startle response and prepulse inhibition in adolescent and adult rats.

Authors:  Steven Craig Brunell; Linda Patia Spear
Journal:  Psychopharmacology (Berl)       Date:  2006-04-25       Impact factor: 4.530

Review 2.  Acute opioid dependence: characterizing the early adaptations underlying drug withdrawal.

Authors:  Andrew C Harris; Jonathan C Gewirtz
Journal:  Psychopharmacology (Berl)       Date:  2005-02-05       Impact factor: 4.530

3.  5-HT2 receptor mechanisms of the dorsal periaqueductal gray in the conditioned and unconditioned fear in rats.

Authors:  Luciana Chrystine Oliveira; Ana Carolina Broiz; Carlos Eduardo de Macedo; J Landeira-Fernandez; Marcus Lira Brandão
Journal:  Psychopharmacology (Berl)       Date:  2007-01-05       Impact factor: 4.530

4.  A leptin-regulated circuit controls glucose mobilization during noxious stimuli.

Authors:  Jonathan N Flak; Deanna Arble; Warren Pan; Christa Patterson; Thomas Lanigan; Paulette B Goforth; Jamie Sacksner; Maja Joosten; Donald A Morgan; Margaret B Allison; John Hayes; Eva Feldman; Randy J Seeley; David P Olson; Kamal Rahmouni; Martin G Myers
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

5.  Distinct ensembles of medial prefrontal cortex neurons are activated by threatening stimuli that elicit excitation vs. inhibition of movement.

Authors:  Lindsay R Halladay; Hugh T Blair
Journal:  J Neurophysiol       Date:  2015-05-13       Impact factor: 2.714

6.  Blockade of the GLT-1 Transporter in the Central Nucleus of the Amygdala Induces both Anxiety and Depressive-Like Symptoms.

Authors:  Catherine S John; Elizabeth I Sypek; William A Carlezon; Bruce M Cohen; Dost Öngür; Anita J Bechtholt
Journal:  Neuropsychopharmacology       Date:  2015-01-14       Impact factor: 7.853

7.  Bi-directional modulation of bed nucleus of stria terminalis neurons by 5-HT: molecular expression and functional properties of excitatory 5-HT receptor subtypes.

Authors:  J-D Guo; S E Hammack; R Hazra; L Levita; D G Rainnie
Journal:  Neuroscience       Date:  2009-09-22       Impact factor: 3.590

8.  Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice.

Authors:  Victoria B Risbrough; Richard L Hauger; Mary Ann Pelleymounter; Mark A Geyer
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

9.  Amygdalar GABAergic-rich neural grafts attenuate anxiety-like behavior in rats.

Authors:  Miles Gregory Cunningham; Caroline Martine Connor; William A Carlezon; Edward Meloni
Journal:  Behav Brain Res       Date:  2009-06-17       Impact factor: 3.332

10.  Prefrontal infralimbic cortex mediates competition between excitation and inhibition of body movements during pavlovian fear conditioning.

Authors:  Lindsay R Halladay; Hugh T Blair
Journal:  J Neurosci Res       Date:  2016-03-21       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.